The Recently-Posted Article Includes Plenty of Helpful Information about NovaBelle Cream and the NovaBelle Company

LOS ANGELES, CA / ACCESSWIRE / March 25, 2019 / The founders of NovaBelle are pleased to announce that their signature product, NovaBelle Cream, was recently featured in an article on the HealthyFitnessBlog website.

To read the new article in its entirety and learn more about the age defying moisturizer, please check out https://www.healthyfitnessblog.com/novabelle-cream-breaking-buzz-new-skincare-product/.

As a company spokesperson noted, the article, which is titled “NovaBelle Cream: Breaking Down All the Buzz on this New Skincare Product,” offers readers a lot of helpful information about the skin care cream and the NovaBelle company.

As Wendy Thomas, the author of the article noted, after seeing that NovaBelle Cream had received a great deal of attention online, she decided to take a look at the cream herself to see if it was worth the buzz that has created.

“Men and women can use NovaBelle, but it is predominately something women use on a consistent basis,” Thomas noted in the article, adding that from her research, she has found that many people are extremely satisfied with how quickly the cream can work and show results.

For example, as Thomas found in her research of a number of blogs devoted to NovaBelle, users were very satisfied with everything about the company. From the cream itself to the customer service, everything was professionally done, Thomas noted.

NovaBelle Cream is so effective, Thomas wrote, other skincare brands are also taking note of the product. From helping to treat dark circles around the eyes and lessen the appearance of wrinkles to working along with facial medications for conditions like acne and psoriasis, the author concluded that NovaBelle Cream lives up to its positive reviews.

Thomas also addressed NovaBelle Cream’s price, which typically retails for $97.99.

“The reviews from those who have tried the cream are very positive,” Thomas noted. In addition, Thomas pointed out that the NovaBelle company will fully stands by their product.

“If a person is not fully persuaded to commit right away, they can sign up for a 14 day trial offer that is just $4.99. That offer can be found directly on TryNovabelleCream.com for those new shoppers.”

About NovaBelle:

NovaBelle, founded by a team of industry experts, is a premiere age defying moisturizer that can help women eliminate the appearance of dark circles, wrinkles, and counter the effects of stress. Learn more about NovaBelle by visiting their official website at https://www.trynovabellecream.com/.

Contact:

Ernesto Mcguire
admin@rocketfactor.com
(949) 555-2861

SOURCE: NovaBelle

ReleaseID: 540043

UNITED KINGDOM / ACCESSWIRE / March 25, 2019 / GHP Magazine has awarded InnerScope Hearing Technologies, (“InnerScope”) Best Hearing Aid Manufacturer 2019 – USA & GHP Award for Innovation in Direct-to-Consumer Hearing Aid Delivery Process in the 2019 Biotechnology Awards.

Covering a variety of verticals, including bio agriculture, bio services, bio industrial and biopharmaceutical, the biotechnology market will be under the microscope in GHP Magazine’s, 2019 Biotechnology Awards.

Boasting impressive market value growth with no signs of slowing, endeavours in biotechnology continue to make advancements in the laboratories as well as in the boardrooms, advancements which the lives of all, across the globe. It is for this reason, we at GHP are dedicated to bringing InnerScope’s accomplishments to the forefront of the community with our award platform.

Since its inception in 2012, InnerScope has been disrupting the global hearing aid industry, which is worth more than 10 billion dollars.

Throughout the past seven years, InnerScope has been working towards achieving its mission: to develop new innovative technologies in Hearing Products for the 1.2 billion people around the world suffering from hearing impairment or hearing related issues. InnerScope is deploying its Hearing & Hearing Health Products to solve the numerous medical and cognitive issues caused by the world-wide epidemic of untreated hearing loss due to high cost and low accessibility of hearing aids and other related hearing products or hearing related treatment therapies. To find out more information of what led InnerScope to become what they are today and other award winners stories, click on the link 2019 Biotechnology Awards recipient supplement

Steve Simpson, Awards Coordinator commented on the awards and their deserving winners: “Through this awards programme, GHP honours a range of companies active within the sector. It is with great pride that I congratulate InnerScope Hearing Technologies for its hard work across the hearing aid development space and wish the team the best of luck for the future.”

About GHP Magazine

Global Health and Pharma magazine is global information sharing platform & a multi-disciplinary member’s community. The publication was established to enhance communication networks & collaboration across all themes and disciplines within three main categories; Human, Animal & Environmental Health. To find out more please visit http://www.ghp-news.com/

About InnerScope Hearing Technologies (OTCQB: INND)

InnerScope Hearing Technologies Inc. is a manufacturer and Direct-to-Consumer (“DTC”) distributor/retailer of FDA-Registered Hearing Aids, Personal Sound Amplifiers Products, (“Hearing Products”) Hearing Related Treatment Therapies, Doctor-Formulated Dietary Hearing Supplements and proprietary CDB Oil for Tinnitus (“Hearing Health Products”) is a rapidly expanding consolidator of the hearing aid industry. Management is applying decades of profitable industry experience and technology to an antiquated and disjointed industry, unlocking scale and efficiency, which will serve all of InnerScope’s stakeholders. Its direct-to-consumer model is revolutionizing the industry with its Walmart.com relationship representing a paramount shift in the consumption of hearing aids by the hearing impaired.

In addition, InnerScope plans to continue to open, acquire, and operate a physical chain of audiological and retail hearing device clinics. InnerScope’s mission is to serve approximately 1.2 billion people around the globe that are suffering with 25 db or greater hearing loss across the entire hearing impaired vertical from R&D and manufacturing through direct consumer sales and services. To find out more please visit: https://www.innd.com/

SOURCE: Innerscope Hearing Technologies, Inc.

ReleaseID: 540006

Signing of definitive agreement expected in early Q2
First orders expected in early Q3

SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. (“Falcon”) (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet.

NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.

Falcon Chairman and Chief Executive Officer William J. Delgado stated, “NeutriSci International has certain knowledge, technology and IP to create sublingual tablets for the delivery of nutraceuticals and vitamins including CBD, in which these CBD tablets have better absorption rates than other nutraceuticals and vitamins. As we have previously announced, we plan on meeting early core goals including initial product introduction by the end of April 2019.”

Mr. Delgado continued, “An integral part of our plan going forward is to have short-term goals as well as long-term goals. Developing a CBD product that has better absorption rates than our competition’s products is part of our long-term plan to create a competitive advantage. We believe that NeutriSci has certain technologies that will allow us to meet our internal specifications of a sublingual product which will add to our initial product line. If all goes according to plan, this CBD sublingual tablet will be available for sale by Q3 2019.”

Mr. Delgado concluded his comments by saying, “We chose NeutriSci because they already have proven they have the technology we desire, and they have demonstrated an ability to bring products to market which are currently being marketed throughout North America. They are the perfect partner.”

Glen Rehman, CEO of NeutriSci International said, “We are pleased at the prospects of offering Falcon an effective delivery method to bring an additional CBD product to the US marketplace. We will be working directly with Falcon to establish a long-term working relationship to develop and launch multiple ground-breaking products and expect revenue from this collaboration in Q3.”

About Falcon Technologies

Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company’s mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy
®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.

Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.

For more information, please visit: www.neutrisci.com.

William Delgado

djwllc@hotmail.com
775-443-4740

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE: Falcon Technologies

ReleaseID: 539947

PLAYA VISTA, CA / ACCESSWIRE / March 25, 2019 / American Premium Water Corporation (OTC: HIPH) (“APWC”) has closed the acquisition of the CBD topical and balm brand plant + body essentials (https://www.plantbodyessentials.com/). Restricted preferred shares were used to pay for the acquisition. In advance of the closing, the Company has begun engaging multiple mass-retailers about selling plant + body’s products.

CEO American Premium Water Corporation, Ryan Fishoff commented, “I am happy to announce that the Company has completed its acquisition of plant + body essentials. This brand is a great addition to the portfolio and is another step towards fulfilling the Company’s vision of establishing itself as one of the premier marketer and distributor of CBD infused consumer products. A number of our distributors have been asking for other CBD products (besides beverages) and this acquisition will give the Company more avenues to leverage existing distribution contacts and generate increased topline revenue. I believe this brand will add significant revenue to the Company and will expand the Company’s product offerings, allowing us to enter new channels that we would not have before, including many beauty retail channels. I see the opportunity for CBD products in the beauty and cosmetics sector to be as large as infused beverages; this acquisition along with our previous deal with Canyon Create gives the Company formidable entries into this space.”

The Company will group plant + body with Canyon Create, leveraging its existing infrastructure which is based in southern California. Before the acquisition, Canyon Create’s portfolio included Vanexxe, the topical cosmetic that masks varicose veins, which recently launched its new website (www.vanexxe.com). A CBD-infused version of varicose vein solution will be launched in the coming months, and the Company is working on launching Prickly Pear, a CBD and CBG infused topical that will combat acne later this year. The addition of plant + body gives the Company a diverse suite of cosmetic products that can offer an attractive bundle package to big box beauty and cosmetic chains.

“The initial feedback from our retailers has been very positive for plant + body. Now that we have closed the transaction, we can actively begin to solicit sales of the product. We have also been getting feedback that plant + body is a good compliment to our water products and other cosmetic products. We are looking at experimenting with different bundle packages of products, and potentially offering monthly subscription services, which a few retailers have inquired about. The big box retail landscape is starting to open up to CBD infused products. It was great to hear that CVS will begin selling CBD infused products in selected states. The Company has already begun reaching out to our contacts and distribution partners to pursue these opportunities. There is still many other channels that represent larger opportunities that the Company is also pursuing. At the end of the day, I am confident the Company will be able to promote our products that will get retailers attention and have the products quality will be superior so that customers will be repeat buyers. I look forward to updating shareholders on the Company’s progress and initial sales of plant + body in the coming weeks.” concluded Mr. Fishoff

About American Premium Water Corp.

American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of hydrogen and Nano technologies paired with cannabidiol (CBD) to treat health disorders and enhance the quality of life. This business model aims to market emerging fashion brands by leveraging classic retail partners and incorporating disruptive blockchain technologies to expand the retail footprint. The company’s portfolio includes the LALPINA Hydro and LALPINA Hydro CBD brands (www.LalpinaInc.com), LALPINA Productions, LALPINA Records, Gents (www.gentsco.com), Worthy, and blockchain platform FashionCoinX (www.FashionCoinX.com).

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). American Premium Water Corporation cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management. Actual results could differ materially from current projections or implied results. American Premium Water Corporation undertakes no obligation to revise these statements following the date of this news release. Additional details of the Company’s business can be found in its public disclosures as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

This press release is issued on behalf of the Board of Directors of American Premium Water Corporation

Contact Information:

Media Contact
Email: info@americanpremiumwater.com
+1(888) 983-0054

SOURCE: HIPH

ReleaseID: 540005

CHARLOTTESVILLE, VA / ACCESSWIRE / March 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed a Registration Statement on Form S-1 on March 22, 2019, to update certain information in the Registration Statement on Form S-1 that was declared effective on July 26, 2018. The update includes the information contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on February 19, 2019.

The Company is also seeking to register 125,000 shares of common stock under the Registration Statement on Form S-1 filed on March 22, 2019, in order to fulfill a contractual obligation to a prior holder of the Company’s warrants and notes. The newly filed registration statement on Form S-1 is subject to review by the SEC before becoming effective.

”It is important to note that by the filing of this Registration Statement on Form S-1, the Company is not offering any new or additional securities,” said Joseph Truluck, Chief Financial Officer and Chief Operating Officer of Adial Pharmaceuticals. ” At this time, the Company is not seeking to raise additional capital and we believe that our current cash-on-hand meets our budget requirements for our planned Phase 3 clinical trial of AD04 for persons suffering from Alcohol Use Disorder.”

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (”AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

Forward Looking Statements

This communication contains certain ”forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words ”believes,””expects,””anticipates,””intends,””projects,””estimates,””plans” and similar expressions or future or conditional verbs such as ”will,””should,””would,””may” and ”could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the effectiveness of the Registration Statement on Form S-1 filed on March 22, 2019 . Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, the timing of the effectiveness of the Registration Statement on Form S-1 filed on March 22, 2019, the timing of the commencement of a Phase 3 clinical trial and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our registration statement on Form S-1 that we have filed with the SEC and the final prospectus and our Current Report on Form 10-K for the period ended December 31, 2018. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Crescendo Communications, LLC
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceuticals, Inc.

ReleaseID: 540050

AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
Dr. Altschuler, the founder and Chairman of the Board of Spark Therapeutics Inc. (ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.

BALTIMORE, MD / ACCESSWIRE / March 25, 2018 / AsclepiX Therapeutics, Inc, a biopharmaceutical company focused on developing vital new therapies based on a novel collagen IV-derived peptide called AXT107, announces that Steven Altschuler, MD has joined its Board of Directors. Dr. Altschuler, who formerly held Chief Executive positions at the Children’s Hospital of Pennsylvania (CHOP) and University of Miami Health System (UMHS), brings significant strategic and operational experience to AsclepiX. As a Board Member, Dr. Altschuler will help AsclepiX succeed and scale as it commercializes its flagship product, AXT107, and their products for cancer.

Dr. Altschuler has 18 years of experience growing healthcare organizations in business and leadership capacities. Trained as a pediatric gastroenterologist, he was appointed in 2000 as President & CEO at CHOP, where he also chaired the Department of Pediatrics. For 15 years, he played a pivotal role transforming CHOP from a traditional academic medical center to a highly integrated, value-based translational health system characterized by world-class clinical care. Under his purview, the organization enjoyed financial success and earned industry accolades, ranking as the #1 children’s hospital by US News and World Report 10 times during his 15-year tenure – and the #2 hospital during the remaining 5 times. He then went on to serve as CEO and Executive Vice President of UMHS, where he restructured the clinical delivery system into a CMS, Perspective Payment System (PPS)-exempt unified academic medical center under a single state license.

In 2013, Dr. Altschuler founded Spark Therapeutics, Inc. (NASDAQ: ONCE) based on technology and know-how developed over two decades at Children’s Hospital of Philadelphia (CHOP). He serves as Chairman of the Board at Spark Therapeutics, Inc., a fully integrated, commercial company committed to discovering, developing and delivering gene therapies across multiple therapeutic categories. In 2017, Spark gained FDA approval for LUXTURNA® (voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and which is currently marketed in the US. The European Commission granted marketing authorization for LUXTURNA in 2018. Most recently, Spark Therapeutics, Inc. is in the process of being acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $4.8 billion.

“The AsclepiX team is proud to make Dr. Altschuler a member of our Board,” said Wendy Perrow, CEO of AsclepiX Therapeutics. “His track record of success in the development and approval of a novel gene therapy for blindness due to inherited retinal disease should prove invaluable to our team as we move into clinical development of AXT107 for acquired retinal diseases, including Diabetic Macular Edema and wet Aged-Related Macular Degeneration. Furthermore, his expertise in developing technology that originated in the academic laboratories of CHOP will translate well to AsclepiX, which is developing novel therapeutics through a peptide platform developed in the laboratories at John’s Hopkins University. Dr. Altschuler’s perspective and guidance will be invaluable as we continue to innovate and bring exciting new therapies to the ophthalmic and oncology markets.”

In addition to his work with Spark and AsclepiX, Dr. Altschuler currently holds leadership and advisory positions on several corporate boards, including Adtalem Global Education (Member, Board of Directors) and WW (formerly Weight Watchers International; Member, Board of Directors). He previously held board positions at Mead Johnson Nutrition Company and the Leonard Davis Institute of Healthcare Economics at the Wharton School, University of Pennsylvania.

About AsclepiX Therapeutics, Inc.
AsclepiX Therapeutics Inc. is transforming the treatment of ocular diseases and cancer with a singular focus on a novel peptide platform with the power to inhibit and potentially even reverse disease progression. The mechanism of action of AXT107 targets multiple pathways, including inhibiting vascular endothelial growth factor receptor 2 (VEGFR2) and activating Tie2, two pathways that promote formation of blood vessels and leakage of fluid in the diseased retina that may be dosed 1 – 2 times per year. AsclepiX is initially focused on ocular diseases currently treated with anti-VEGF monotherapies. Learn more at www.asclepix.com.

Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of AsclepiX Therapeutics, Inc. products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AsclepiX Therapeutics, Inc. undertakes no obligation to update any forward-looking statements for any reason.

Media contact:
Amy Phillips
amy@pascaslecommunications.com
412-327-9499

SOURCE: AsclepiX Therapeutics, Inc.

ReleaseID: 539902